Document
Table of Contents

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2017
 
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 1-815 
E. I. du Pont de Nemours and Company
(Exact Name of Registrant as Specified in Its Charter)
Delaware
 
51-0014090
(State or other Jurisdiction of
 
(I.R.S. Employer
Incorporation or Organization)
 
Identification No.)
974 Centre Road, Wilmington, Delaware 19805
(Address of Principal Executive Offices)
 
(302) 774-1000
(Registrant’s Telephone Number)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x   No  o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that registrant was required to submit and post such files.)  Yes  x   No  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer x
 
Accelerated Filer o
 
 
 
Non-Accelerated Filer o
 
Smaller reporting company o
 
 
 
 
 
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).  Yes  o   No  x
The Registrant had 100 shares of common stock, $0.30 par value, outstanding at September 30, 2017, all of which are held by DowDuPont Inc.
 
 

Table of Contents

E. I. DU PONT DE NEMOURS AND COMPANY

Table of Contents
 
The terms “DuPont” or the “company” as used herein refer to E. I. du Pont de Nemours and Company and its consolidated subsidiaries, or to E. I. du Pont de Nemours and Company, as the context may indicate. 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2
Table of Contents

PART I.  FINANCIAL INFORMATION
 
Item 1.
CONSOLIDATED FINANCIAL STATEMENTS
 
E. I. du Pont de Nemours and Company
Consolidated Statements of Operations (Unaudited)
 
 
Successor
Predecessor
(In millions, except per share amounts)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Net sales
$
1,735

$
2,991

$
4,646

$
17,281

$
18,306

Cost of goods sold
1,511

1,975

2,997

10,205

10,923

Other operating charges
 
136

172

504

490

Research and development expense
116

278

378

1,064

1,159

Selling, general and administrative expenses
267

798

970

3,306

3,227

Amortization of intangibles
89

 
 
 
 
Restructuring and asset related charges - net
40

11

172

323

162

Integration and separation costs
71

 
 
 
 
Sundry income (expense) - net
88

(112
)
(15
)
166

407

Interest expense
27

71

93

254

278

(Loss) Income from continuing operations before income taxes
(298
)
(390
)
(151
)
1,791

2,474

(Benefit from) provision for income taxes on continuing operations
(23
)
(132
)
(85
)
149

559

(Loss) Income from continuing operations after income taxes
(275
)
(258
)
(66
)
1,642

1,915

(Loss) Income from discontinued operations after income taxes
(20
)
29

72

119

347

Net (loss) income
(295
)
(229
)
6

1,761

2,262

Net (loss) income attributable to noncontrolling interests
(2
)
5

4

20

14

Net (loss) income attributable to DuPont
$
(293
)
$
(234
)
$
2

$
1,741

$
2,248

Basic (loss) earnings per share of common stock:
 
 
 
 
 
Basic (loss) earnings per share of common stock from continuing operations


$
(0.30
)
$
(0.08
)
$
1.86

$
2.17

Basic earnings per share of common stock from discontinued operations


0.03

0.08

0.13

0.40

Basic (loss) earnings per share of common stock


$
(0.27
)
$
—

$
2.00

$
2.56

Diluted (loss) earnings per share of common stock:
 
 
 
 
 
Diluted (loss) earnings per share of common stock from continuing operations


$
(0.30
)
$
(0.08
)
$
1.85

$
2.16

Diluted earnings per share of common stock from discontinued operations


0.03

0.08

0.13

0.39

Diluted (loss) earnings per share of common stock


$
(0.27
)
$
—

$
1.99

$
2.55

Dividends declared per share of common stock


$
0.38

$
0.38

$
1.14

$
1.14


See Notes to the Consolidated Financial Statements beginning on page 9.

3
Table of Contents

E. I. du Pont de Nemours and Company
Consolidated Statements of Comprehensive Income (Unaudited)

 
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Net (loss) income
$
(295
)
$
(229
)
$
6

$
1,761

$
2,262

Other comprehensive (loss) income - net of tax:
 








Unrealized gains on investments
—

—

5

—

11

Cumulative translation adjustments
(572
)
389

114

1,042

187

Adjustments to pension benefit plans
—

50

(16
)
247

(1,271
)
Adjustments to other benefit plans
—

3

(11
)
10

(230
)
Derivative instruments
—

1

(2
)
(10
)
32

Total other comprehensive (loss) income
(572
)
443

90

1,289

(1,271
)
Comprehensive (loss) income
(867
)
214

96

3,050

991

Comprehensive (loss) income attributable to noncontrolling interests - net of tax
(2
)
5

4

20

14

Comprehensive (loss) income attributable to DuPont
$
(865
)
$
209

$
92

$
3,030

$
977


See Notes to the Consolidated Financial Statements beginning on page 9.


4
Table of Contents


E. I. du Pont de Nemours and Company
Condensed Consolidated Balance Sheets (Unaudited)
 
Successor
Predecessor
(In millions, except share amounts)
September 30,
2017
December 31,
2016
Assets
 

 

Current assets
 

 

Cash and cash equivalents
$
4,754

$
4,548

Marketable securities
1,826

1,362

Accounts and notes receivable - net
7,898

4,959

Inventories
8,783

5,350

Other current assets
371

505

Assets held for sale- current
3,171

789

Total current assets
26,803

17,513

Investment in nonconsolidated affiliates
1,675

649

Property, plant and equipment - net of accumulated depreciation (September 30, 2017 - $121; December 31, 2016 - $14,164)
11,902

8,851

Goodwill
45,213

4,169

Other intangible assets
27,668

3,664

Deferred income taxes
491

3,308

Other assets
2,068

1,810

Total Assets
$
115,820

$
39,964

Liabilities and Equity
 

 

Current liabilities
 

 

Short-term borrowings and capital lease obligations
$
5,920

$
429

Accounts payable
3,694

3,678

Income taxes payable
134

101

Accrued and other current liabilities
2,477

4,650

Liabilities held for sale - current
108

74

Total current liabilities
12,333

8,932

Long-Term Debt
9,815

8,107

Other Noncurrent Liabilities
 
 
Deferred income tax liabilities
9,443

425

Pension and other post employment benefits - noncurrent
8,015



Other noncurrent obligations
1,976

12,304

Total noncurrent liabilities
29,249

20,836

Stockholders’ equity
 

 

Preferred stock, without par value – cumulative; 23,000,000 shares authorized;
     issued at September 30, 2017 and December 31, 2016:
 
 
$4.50 Series – 1,673,000 shares (callable at $120)
169

167

$3.50 Series – 700,000 shares (callable at $102)
70

70

Common stock, $.30 par value; 1,800,000,000 shares authorized; issued at September 30, 2017 - 100 and December 31, 2016 – 950,044,000
—

285

Additional paid-in capital
74,706

11,190

(Accumulated deficit) retained earnings
(295
)
14,924

Accumulated other comprehensive loss
(572
)
(9,911
)
Common stock held in treasury, at cost (Shares: December 31, 2016 – 87,041,000)
—

(6,727
)
Total DuPont stockholders’ equity
74,078

9,998

Noncontrolling interests
160

198

Total equity
74,238

10,196

Total Liabilities and Equity
$
115,820

$
39,964

 
See Notes to the Consolidated Financial Statements beginning on page 9.

5
Table of Contents

E. I. du Pont de Nemours and Company
Condensed Consolidated Statements of Cash Flows (Unaudited)
 
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Operating activities
 
 
 
Net (loss) income
$
(295
)
$
1,761

$
2,262

Adjustments to reconcile net (loss) income to cash used for operating activities:






Depreciation and amortization
200

749

979

Provision for deferred income tax
211





Net periodic pension (benefit) cost
(28
)
295

474

Pension contributions
(19
)
(3,024
)
(427
)
Net gain on sales of property, businesses, consolidated companies, and investments
(1
)
(204
)
(385
)
Restructuring and asset related charges - net
40

 
 
Asset related charges
 
279

247

Amortization of inventory step-up
429





Other net (gain) loss
(61
)
481

421

Change in operating assets and liabilities - net
(786
)
(4,286
)
(4,598
)
Cash used for operating activities
(310
)
(3,949
)
(1,027
)
Investing activities
 

 
 

Capital expenditures
(92
)
(687
)
(759
)
Proceeds from sales of property, businesses, and consolidated companies - net of cash divested
1

300

240

Acquisitions of businesses - net of cash acquired
3

(246
)
—

Investments in and loans to nonconsolidated affiliates
—

(22
)
(2
)
Purchases of investments
(26
)
(5,457
)
(1,462
)
Proceeds from sales and maturities of investments
1,049

3,977

1,294

Foreign currency exchange contract settlements


(206
)
(370
)
Other investing activities - net
—

(41
)
(16
)
Cash provided by (used for) investing activities
935

(2,382
)
(1,075
)
Financing activities
 

 
 

Change in short-term (less than 90 days) borrowings
588

3,610

2,624

Proceeds from issuance of long-term debt
—

2,734

783

Payments on long-term debt
(41
)
(229
)
(831
)
Repurchase of common stock


—

(416
)
Proceeds from exercise of stock options
11

235

118

Dividends paid to stockholders
(326
)
(666
)
(1,004
)
Other financing activities
(2
)
(52
)
(44
)
Cash provided by financing activities
230

5,632

1,230

Effect of exchange rate changes on cash
(69
)
187

24

Cash reclassified as held for sale
$
(37
)
$
(31
)
$
(19
)
Increase (decrease) in cash and cash equivalents
$
749

$
(543
)
$
(867
)
Cash and cash equivalents at beginning of period
4,005

4,548

5,228

Cash and cash equivalents at end of period
$
4,754

$
4,005

$
4,361

See Notes to the Consolidated Financial Statements beginning on page 9.


6
Table of Contents

E.I. du Pont de Nemours and Company
Consolidated Statements of Equity (Unaudited)

(In millions)
Preferred Stock
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comp Loss
Treasury Stock
Non-controlling Interests
Total Equity
Predecessor
 
 
 
 
 
 
 
 
Balance at January 1, 2016
$
237

$
288

$
11,081

$
14,510

$
(9,396
)
(6,727
)
207

$
10,200

Net income



2,248



14

2,262

Other comprehensive loss




(1,271
)


(1,271
)
Common dividends ($1.14 per share)



(1,001
)


(12
)
(1,013
)
Preferred dividends



(7
)



(7
)
Common stock issued - compensation plans


207





207

Common stock repurchased

(1
)



(416
)
(2
)
(419
)
Common stock retired


(70
)
(343
)

416


3

Sale of a majority interest in a consolidated subsidiary


(4
)



(4
)
(8
)
Balance at September 30, 2016
$
237

$
287

$
11,214

$
15,407

$
(10,667
)
$
(6,727
)
$
203

$
9,954

 
 
 
 
 
 
 
 
 
Balance at January 1, 2017
$
237

$
285

$
11,190

$
14,924

$
(9,911
)
$
(6,727
)
$
198

10,196

Net income



1,741



20

1,761

Other comprehensive income




1,289



1,289

Common dividends ($1.14 per share)



(991
)


(4
)
(995
)
Preferred dividends



(7
)



(7
)
Common stock issued - compensation plans

2

273





275

Common stock repurchased







—

Common stock retired

(26
)
(1,044
)
(5,657
)

6,727


—

Sale of a majority interest in a consolidated subsidiary






(2
)
(2
)
Balance at August 31, 2017
$
237

$
261

$
10,419

$
10,010

$
(8,622
)
$
—

$
212

$
12,517

 
 
 
 
 
 
 
 
 
 
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comp Loss
Treasury Stock
Non-controlling Interests
Total Equity
Successor
 
 
 
 
 
 
 
 
Balance at September 1, 2017 (remeasured upon Merger)
$
239

$
—

$
74,680

$
—

$
—

$
—

$
162

$
75,081

Net loss



(293
)


(2
)
(295
)
Other comprehensive loss




(572
)


(572
)
Issuance of parent company stock


11





11

Stock-based compensation


15





15

Other



(2
)



(2
)
Balance at September 30, 2017
$
239

$
—

$
74,706

$
(295
)
$
(572
)
$
—

$
160

$
74,238


See Notes to the Consolidated Financial Statements beginning on page 9.


7
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
E.I. du Pont de Nemours and Company

 
 
Notes to the Consolidated Financial Statements
 


Table of Contents

Note
 
Page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19



8
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 1.  Summary of Significant Accounting Policies

Interim Financial Statements
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included.  Results for interim periods should not be considered indicative of results for a full year.  These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto contained in the company’s Annual Report on Form 10-K for the year ended December 31, 2016, collectively referred to as the “2016 Annual Report”.  The interim Consolidated Financial Statements include the accounts of the company and all of its subsidiaries in which a controlling interest is maintained.

Principles of Consolidation and Basis of Presentation
DowDuPont Inc. ("DowDuPont") was formed on December 9, 2015 to effect an all-stock, merger of equals strategic combination between The Dow Chemical Company ("Dow") and E. I. du Pont de Nemours and Company ("DuPont") (the "Merger Transaction"). On August 31, 2017 at 11:59 pm ET, (the "Merger Effectiveness Time") pursuant to the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the "Merger Agreement"), Dow and DuPont each merged with wholly owned subsidiaries of DowDuPont ("Mergers") and, as a result of the Mergers, Dow and DuPont became subsidiaries of DowDuPont (collectively, the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. DowDuPont intends to pursue, subject to the receipt of approval by the board of directors of DowDuPont, the separation of the combined company's agriculture business, specialty products business and material science business through a series of tax-efficient transactions (collectively, the Intended Business Separations).

For purposes of DowDuPont's financial statement presentation, Dow was determined to be the accounting acquirer in the Merger and DuPont's assets and liabilities are reflected at fair value as of the Merger Effectiveness Time. In connection with the Merger and the related accounting determination, DuPont has elected to apply push-down accounting and reflect in its financial statements, the fair value of its assets and liabilities. DuPont's interim Consolidated Financial Statements for periods following the close of the Merger are labeled “Successor” and reflect DowDuPont’s basis in the fair values of the assets and liabilities of DuPont. All periods prior to the closing of the Merger reflect the historical accounting basis in DuPont's assets and liabilities and are labeled “Predecessor.” The interim Consolidated Financial Statements and Footnotes include a black line division between the columns titled "Predecessor" and "Successor" to signify that the amounts shown for the periods prior to and following the Merger are not comparable. See Note 3 for additional information on the Merger.

Transactions between DowDuPont, DuPont, Dow and their affiliates and other associated companies are reflected in the Successor consolidated financial statements and disclosed as related party transactions when material. Related party transactions with DowDuPont and Dow and their affiliates were not material as of September 30, 2017 and for the period September 1 through September 30, 2017.

As a condition of the regulatory approval for the Merger Transaction, the company is required to divest certain assets related to its Crop Protection business and research and development ("R&D") organization, specifically the company’s Cereal Broadleaf Herbicides and Chewing Insecticides portfolios, including Rynaxypyr®, Cyazypyr® and Indoxacarb as well as the Crop Protection R&D pipeline and organization, excluding seed treatment, nematicides, and late-stage R&D programs. On March 31, 2017, the company entered into a definitive agreement (the "FMC Transaction Agreement") with FMC Corporation ("FMC"). Under the FMC Transaction Agreement, FMC will acquire the Crop Protection business and R&D assets that DuPont is required to divest in order to obtain European Commission ("EC") approval of the Merger Transaction as described above, (the "Divested Ag Business") and DuPont has agreed to acquire certain assets relating to FMC’s Health and Nutrition segment, excluding its Omega-3 products, (the "Acquired H&N Business") (collectively, the "FMC Transactions"). This transaction closed on November 1; see Note 4 for further information regarding the closing.


9
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The assets and liabilities related to the Divested Ag Business at September 30, 2017 are presented as held for sale in the interim Consolidated Balance Sheet. The sale of the Divested Ag Business meets the criteria for discontinued operations and as such, earnings are included within income from discontinued operations after income taxes for all periods presented. The sum of the individual earnings per share amounts from continuing operations and discontinued operations may not equal the total company earnings per share amounts due to rounding. The cash flows and comprehensive income related to the Divested Ag Business have not been segregated and are included in the interim Condensed Consolidated Statements of Cash Flows and Consolidated Statements of Comprehensive Income, respectively, for all periods presented. Amounts related to the Divested Ag Business are consistently included or excluded from the Notes to the interim Consolidated Financial Statements based on the respective financial statement line item. See Note 4 for further information.

On July 1, 2015, the company completed the separation of its Performance Chemicals segment through the spin-off of all of the issued and outstanding stock of The Chemours Company ("Chemours"). In accordance with GAAP, the results of operations of the Performance Chemicals segment are presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. The sum of the individual earnings per share amounts from continuing operations and discontinued operations may not equal the total company earnings per share amounts due to rounding.

Certain reclassifications of prior year's data have been made to conform to current year's presentation. As described in Note 2, effective January 1, 2017, the company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update ("ASU") No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. In conjunction with the adoption of this ASU, the company retrospectively reclassified cash flows related to income tax impacts associated with employee share-based payments in the interim Condensed Consolidated Statements of Cash Flows, as described in Note 2.

Significant Accounting Policies
The company's accounting policies described below have been aligned with DowDuPont as a result of the Merger. See Note 1 in the 2016 Annual Report for information on DuPont's other significant accounting policies.

Cost of Goods Sold
Successor periods - Cost of goods sold primarily includes the cost of manufacture and delivery, ingredients or raw materials, direct salaries, wages and benefits and overhead, non-capitalizable costs associated with capital projects and other operational expenses. 

Predecessor periods - Cost of goods sold primarily includes the cost of manufacture and delivery, ingredients or raw materials, direct salaries, wages and benefits and overhead.

Other Operating Charges
Predecessor periods - Other operating charges includes product claim charges and recoveries, non-capitalizable costs associated with capital projects and other operational expenses. 

Selling, General and Administrative Expenses
Successor periods - Selling, general and administrative expenses primarily include selling and marketing expenses, commissions, functional costs, and business management expenses.

Predecessor periods - Selling, general and administrative expenses primarily include selling and marketing expenses, commissions, functional costs, business management expenses and integration and separation costs.

Integration and Separation Costs
Successor periods - Integration and separation costs includes costs incurred to prepare for and close the Merger, post-Merger integration expenses and costs incurred to prepare for the Intended Business Separations. These costs primarily consist of financial advisory, information technology, legal, accounting, consulting and other professional advisory fees associated with preparation and execution of these activities.

Changes in Accounting and Reporting
Within the Successor period, DuPont made the following changes in accounting and reporting to harmonize its accounting and reporting with DowDuPont.


10
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Within the Successor period of the interim Consolidated Statements of Operations:
•
Included royalty income within net sales. In the Predecessor periods, royalty income is included within sundry income (expense) - net.
•
Eliminated the other operating charges line item. In the Successor period, these charges are included in costs of goods sold, selling, general and administrative expenses and amortization of intangibles.
•
Presented amortization of intangibles as a separate line item. In the Predecessor periods, amortization is included within selling, general and administrative expenses, other operating charges, and research and development expenses
•
Presented integration and separation costs as a separate line item. In the Predecessor periods, these costs are included within selling, general and administrative expenses.
•
Included interest accrued related to unrecognized tax benefits in the provision for income taxes. In the Predecessor period, interest accrued related to unrecognized tax benefits is included in sundry income (expense) - net.

Within the Successor period of the interim Condensed Consolidated Balance Sheets:
•
Included loans to nonconsolidated affiliates within noncurrent receivables. In the Predecessor period, loans are included within investment in nonconsolidated affiliates.
•
Included accrued discounts and rebates within accounts payable. In the Predecessor period, accrued discounts and rebates are included within accrued and other current liabilities.
•
Included non-current pension liabilities within pension and other post employment benefits - noncurrent. In the Predecessor period, non-current pension liabilities are included within other noncurrent obligations.

Within the Successor period of the interim Condensed Consolidated Statements of Cash Flows:
•
Included foreign currency exchange contract settlements within cash flows from operating activities, regardless of hedge accounting qualification. In the Predecessor period, DuPont reflected non-qualified hedge programs, specifically forward contracts, options and cash collateral activity, within cash flows from investing activities. In the Predecessor period, DuPont reflected cash flows from qualified programs within the line item it related to (i.e., revenue hedge cash flows presented within changes from accounts receivable).
•
Aligned the line items within the "change in operating assets and liabilities - net" to the DowDuPont presentation, including accounts and notes receivable, inventories, accounts payable, and other assets and liabilities. In the Predecessor period, the line item "changes in operating assets and liabilities - net" includes accounts and notes receivable, inventories and other operating assets, accounts payable and other operating liabilities, and accrued interest and income taxes.

Use of Estimates
In connection with the Merger, DowDuPont has performed a preliminary allocation of the total consideration exchanged for the DuPont assets and liabilities it acquired using preliminary estimates. The estimates are subject to change as discussed in Note 3.

Segments
Prior to the Merger, DuPont's reportable segments included Agriculture, Electronics & Communication, Industrial Biosciences, Nutrition & Health, Performance Materials, Protection Solutions and Other. Effective with the Merger, DuPont’s business activities are components of its parent company’s business operations. DuPont’s business activities, including the assessment of performance and allocation of resources, will be reviewed and managed by DowDuPont. Information used by the chief operating decision maker of DuPont relates to the company in its entirety. Accordingly, there are no separate reportable business segments for DuPont under Accounting Standards Codification ("ASC") Topic 280 “Segment Reporting” and DuPont's business results are reported in this Form 10-Q as a single operating segment.

Note 2. Recent Accounting Guidance

Recently Adopted Accounting Guidance
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting, which modifies the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when stock awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also allows the company to repurchase more of an employee’s vested shares for tax withholding purposes without triggering liability accounting, and clarifies that all cash payments made to tax authorities on an employee’s behalf for withheld shares should be presented as a financing activity on the statement of cash flows. The company adopted this standard as of January 1, 2017.

11
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The primary impact of adoption was the recognition of excess tax benefits in the company's provision for income taxes rather than additional paid-in capital, which is applied prospectively in accordance with the guidance. Adoption of the new standard resulted in the recognition of $5 million, $30 million and $0 million of excess tax benefits in the company's provision for income taxes rather than additional paid-in capital for the period July 1 through August 31, 2017, the period January 1 through August 31, 2017, and the period September 1 through September 30, 2017, respectively.
The company elected to apply the presentation requirements for cash flows related to excess tax benefits retrospectively to all periods presented which resulted in a decrease to both net cash used for operating activities and net cash provided by financing activities of $22 million for the nine months ended September 30, 2016. The presentation requirements for cash flows related to employee taxes paid for withheld shares resulted in a decrease to both net cash used for operating activities and net cash provided by financing activities of $28 million for the nine months ended September 30, 2016.
The remaining updates required by this standard did not have a material impact to the company’s interim Consolidated Financial Statements.

Accounting Guidance Issued But Not Adopted as of September 30, 2017
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Improvements to Accounting for Hedging Activities. The new guidance expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged items in the financial statements. For cash flow and net investment hedges existing as of the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate measurement of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which an entity adopts. Presentation and disclosure guidance is required to be adopted prospectively. The new standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted in any interim period. All transition requirements and elections should be applied to hedging relationships existing (that is, hedging relationships in which the hedging instrument has not expired, been sold, terminated, or exercised or the entity has not removed the designation of the hedging relationship) on the date of adoption. The effect of adoption should be reflected as of the beginning of the fiscal year of adoption. The company is currently evaluating the impact this guidance will have on the Consolidated Financial Statements and related disclosures.

In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The new guidance requires registrants to present the service cost component of net periodic benefit cost in the same income statement line item or items as other employee compensation costs arising from services rendered during the period. In addition, only the service cost component will be eligible for capitalization in assets. Registrants will present the other components of net periodic benefit cost separately from the service cost component; and, the line item or items used in the income statement to present the other components of net periodic benefit cost must be disclosed. The guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual period. The new standard must be adopted retrospectively for the presentation of the service cost component and the other components of net periodic benefit cost in the income statement, and prospectively for the capitalization of the service cost component of net periodic benefit cost in assets. The company plans to adopt this guidance in the first quarter of 2018 and is currently evaluating the impact on the Consolidated Financial Statements and related disclosures. See Note 15 for the components of net periodic benefit cost.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment. The new guidance eliminates the requirement to determine the fair value of individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments in the new ASU, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. The new standard is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. In connection with the Merger Transaction, the company adopted the policy of the parent company and will perform its annual goodwill impairment test in the fourth quarter. Previously, the annual impairment test was performed in the third quarter. The company is planning to early adopt the new guidance for the annual goodwill impairment test that will be performed in the fourth quarter of 2017.



12
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business. The new guidance narrows the existing definition of a business and provides a framework for evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities (collectively, the "set") is not a business. To be considered a business, the set would need to include an input and a substantive process that together significantly contribute to the ability to create outputs, as defined by the ASU. The guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods, and should be applied prospectively. Early adoption is permitted. The company will adopt this standard on January 1, 2018 and will apply it prospectively to all applicable transactions after the adoption date.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory. The new guidance requires that entities recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, rather than when the asset is sold to an outside party. The guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The new guidance requires adoption on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The company plans to adopt this guidance in the first quarter of 2018 with the expectation that this guidance will have an immaterial impact on the Consolidated Financial Statements and related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments. The new guidance makes eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The new guidance requires adoption on a retrospective basis unless it is impracticable to apply, in which case the company would be required to apply the amendments prospectively as of the earliest date practicable. The company is currently evaluating the impact this guidance will have on the Consolidated Financial Statements and related disclosures, but does not expect there to be a significant impact.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The amendments under the new guidance will require lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability, other than leases that meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Classification will be based on criteria that are largely similar to those applied in current lease accounting. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and the new revenue recognition standard. The new leasing standard will be effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, requiring application at the beginning of the earliest comparative period presented. The company is currently evaluating the impact of adopting this guidance on the Consolidated Financial Statements and related disclosures. The company is the lessee under various agreements for facilities and equipment that are currently accounted for as operating leases. A complete discussion of these leases is included in the company's 2016 Annual Report in Note 15, "Commitments and Contingent Liabilities."

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was further updated in March, April, May and December 2016. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new standard also will result in additional disclosure requirements to describe the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. In July 2015, the FASB approved a deferral of the ASU effective date from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. The company continues to evaluate the impact of the new standard on the Consolidated Financial Statements and related disclosures.  Based on the analysis conducted to date, the company does not believe the impact upon adoption will be material to its Consolidated Financial Statements.  The company plans to adopt the standard in the first quarter of 2018 under the modified retrospective transition method.


13
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 3. Business Combinations

Acquisition of Granular, Inc.
On August 31, 2017, the Company acquired Granular, Inc., a leading provider of software and analytics tools that helps farms improve efficiency, profitability, and sustainability.  The purchase price was approximately $250 million and was primarily allocated to goodwill, developed technology and customer relationships.The fair value of the acquired assets relate to Granular, Inc. are included in the fair value measurement of  DuPont’s assets and liabilities as a result of the application of push down accounting in connection with the Merger discussed below. 

Merger with Dow
Upon completion of the Merger, (i) each share of common stock, par value $0.30 per share, of the company (the “DuPont Common Stock”) was converted into the right to receive 1.2820 fully paid and non-assessable shares of DowDuPont common stock, par value $0.01 per share, ("DowDuPont Common Stock"), in addition to cash in lieu of any fractional shares of DowDuPont Common Stock, and (ii) each share of DuPont Preferred Stock—$4.50 Series and DuPont Preferred Stock—$3.50 Series (collectively, the “DuPont Preferred Stock”) issued and outstanding immediately prior to the Merger Effectiveness Time remains issued and outstanding and was unaffected by the Mergers.

As provided in the Merger Agreement, at the Merger Effectiveness Time, all options relating to shares of DuPont Common Stock that were outstanding immediately prior to the effective time of the Mergers were generally automatically converted into options relating to shares of DowDuPont Common Stock and all restricted stock units and performance based restricted stock units relating to shares of DuPont Common Stock that were outstanding immediately prior to the effective time of the Mergers were generally automatically converted into restricted stock units relating to shares of DowDuPont Common Stock, in each case, after giving effect to appropriate adjustments to reflect the Mergers and otherwise generally on the same terms and conditions as applied under the applicable plans and award agreements immediately prior to the Merger Effectiveness Time. See Note 16 for further discussion.

Prior to the Merger, shares of DuPont Common Stock were registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended and listed on the New York Stock Exchange (the “NYSE”). As a result of the Merger, on August 31, 2017, the company requested that the NYSE withdraw the shares of DuPont Common Stock from listing on the NYSE and filed a Form 25 with the U.S. Securities and Exchange Commission ("SEC") to report that DuPont Common Stock is no longer listed on the NYSE. DuPont continues to have Preferred Stock outstanding and it remains listed on the NYSE. DowDuPont Common Stock is listed and trades on the NYSE, ticker symbol DWDP.

As a condition of the regulatory approval of the Merger, DuPont was required to divest a portion of its Crop Protection business, including certain research and development capabilities. See Note 4 for additional information.

DuPont and Dow intend to pursue, subject to the receipt of approval by the Board of Directors of DowDuPont, the separation of the combined company’s agriculture, specialty products and material science businesses through a series of tax-efficient transactions (collectively, the Intended Business Separations).

Preliminary Allocation of Purchase Price
Based on an evaluation of the provisions of ASC 805, "Business Combinations", Dow was determined to be the accounting acquirer in the Merger. DowDuPont has applied the acquisition method of accounting with respect to the assets and liabilities of DuPont, which have been measured at fair value as of the date of the Merger. In connection with the Merger and the related accounting determination, DuPont has elected to apply push-down accounting and reflect in its financial statements, the fair value of assets and liabilities. Such fair values have been reflected in the Successor Consolidated Financial Statements.

DuPont's assets and liabilities were measured at estimated fair values as of the Merger Effectiveness Time, primarily using Level 3 inputs. Estimates of fair value represent management's best estimate which require a complex series of judgments about future events and uncertainties. Third-party valuation specialists were engaged to assist in the valuation of these assets and liabilities.

The total fair value of consideration transferred for the Merger was approximately $74,680 million. Total consideration is comprised of the equity value of the DowDuPont shares as of the Merger Effectiveness Time, that were issued in exchange for DuPont shares, the cash value for fractional shares, and the portion of DuPont's share awards and share options earned as of the Merger Effectiveness Time. Share awards and share options converted to DowDupont equity instruments, but not vested, were $144 million as of August 31, 2017, which will be expensed over the remaining future vesting period.


14
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The following table summarizes the fair value of consideration exchanged as a result of the Merger:
Consideration                                                                                                                                                                                                 In millions (except exchange ratio)
 
DuPont Common Stock outstanding as of the Merger Effectiveness Time
868.3

DuPont exchange ratio
1.2820

DowDuPont Common Stock issued in exchange for DuPont Common Stock
1,113.2

Fair value of DowDuPont Common Stock issued 1
$
74,195

Fair value of DowDuPont equity awards issued in exchange for outstanding DuPont equity awards 2
485

Total consideration
$
74,680

1.
Amount was determined based on the price per share of Dow Common Stock of $66.65 on August 31, 2017.
2.
Represents the fair value of replacement awards issued for DuPont's equity awards outstanding immediately before the Merger and attributable to the service periods prior to the Merger. The previous DuPont equity awards were converted into the right to receive 1.2820 shares of DowDuPont Common Stock.

The acquisition method of accounting requires, among other things, that identifiable assets acquired and liabilities assumed be recognized on the balance sheet at the fair values as of the acquisition date. In determining the fair value, DowDuPont utilized various forms of the income, cost and market approaches depending on the asset or liability being fair valued. The estimation of fair value required significant judgment related to future net cash flows (including net sales, cost of products sold, selling and marketing costs, and working capital/contributory asset charges), discount rates reflecting the risk inherent in each cash flow stream, competitive trends, market comparables and other factors. Inputs were generally determined by taking into account historical data, supplemented by current and anticipated market conditions, and growth rates.


15
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The table below presents the preliminary fair value that was allocated to DuPont's assets and liabilities based upon fair values as determined by DowDuPont. The valuation process to determine the fair values is not yet complete. The company will finalize the amounts recognized as it obtains the information necessary to complete the analysis, but no later than one year from the date of the Merger. Final determination of the fair values may result in further adjustments to the values presented in the following table.

Fair Value of DuPont Assets and Liabilities as of the Merger Effectiveness Time
 
(In millions)
Fair Value of Assets
 
Cash and cash equivalents
$
4,005

Marketable securities
2,849

Accounts and notes receivable - net
7,851

Inventories
8,886

Other current assets
360

Investment in nonconsolidated affiliates
1,685

Assets held for sale - current

3,184

Property, plant and equipment - net
12,122

Goodwill 1
45,501

Other intangible assets 1
27,844

Deferred income tax assets
487

Other assets
2,076

Total Assets
$
116,850

Fair Value of Liabilities
 
Short-term borrowings and capital lease obligations

$
5,319

Accounts payable
3,283

Income taxes payable
140

Accrued and other current liabilities
3,517

Liabilities held for sale - current

104

Long-term debt
9,878

Deferred income tax liabilities
9,408

Pension and other post employment benefits - noncurrent 2
8,092

  Other noncurrent obligations
2,028

Total Liabilities
$
41,769

Noncontrolling interests
162

Preferred stock
239

Fair Value of Net Assets (Consideration for the Merger)
$
74,680

1.
See Note 11 for additional information.
2.
Includes pension and other post employment benefits as well as long-term disability obligations.

The significant fair value adjustments included in the preliminary allocation of purchase price are discussed below.

Inventories
Inventory is primarily comprised of finished products of $5,115 million, semi-finished products of $3,066 million and raw materials of $705 million. Fair value of finished goods was calculated as the estimated selling price, adjusted for costs of the selling effort and a reasonable profit allowance relating to the selling effort. Fair value of work-in-process inventory was primarily calculated as the estimated selling price, adjusted for estimated costs to complete the manufacturing, estimated costs of the selling effort, as well as a reasonable profit margin on the remaining manufacturing and selling effort. The fair value of raw materials was determined to approximate the historical carrying value. For inventory accounted for under the first-in, first-out method and average cost method, the preliminary fair value step-up of inventory will be recognized in costs of goods sold as the inventory is sold. The pre-tax amount recognized for the period September 1 through September 30, 2017, was $429 million, of which $360 million is reflected in costs of goods sold within loss from continuing operations before income taxes and $69 million is reflected in loss from discontinued operations after income taxes in the Consolidated Statements of Operations. For inventory accounted for under the last-in, first-out ("LIFO") method, the preliminary fair value of inventory becomes the LIFO base layer inventory.


16
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Property, Plant & Equipment
Property, plant and equipment is comprised of land and land improvements of $967 million, buildings of $2,615 million, machinery and equipment of $7,540 million and construction in progress of $1,000 million. The preliminary estimated fair value of property and equipment was primarily determined using a market approach for land and certain types of equipment, and a replacement cost approach for property and equipment. The market approach for certain types of equipment represents a sales comparison that measures the value of an asset through an analysis of sales and offerings of comparable assets. The replacement cost approach used for all other depreciable property and equipment measures the value of an asset by estimating the cost to acquire or construct comparable assets and adjusts for age and condition of the asset.

Goodwill
The excess of the consideration for the Merger over the preliminary net fair value of assets and liabilities was recorded as goodwill. The Merger resulted in the recognition of $45,501 million of goodwill, which is not deductible for tax purposes. Goodwill largely consists of expected cost synergies resulting from the Merger and the Intended Business Separations, the assembled workforce of DuPont and future technology and customers. Cost synergies will be achieved through a combination of workforce consolidations and savings from actions such as procurement synergies, harmonizing energy contracts at large sites, optimizing warehouse and logistics footprints, implementing materials and maintenance best practices and leveraging existing research and development knowledge management systems.

Other Intangible Assets
Other intangible assets primarily consist of customer-related, developed technology, trademarks and trade names and germplasm. The preliminary customer-related value was determined using the excess earnings method while the preliminary developed technology, trademarks and trade names and germplasm values were primarily determined utilizing the relief from royalty method. Both the excess earnings and relief from royalty methods are forms of the income approach. Refer to Note 11 for further information on other intangible assets.

Income Taxes
The deferred income tax assets and liabilities include the expected future federal, state and foreign tax consequences associated with temporary differences between the preliminary fair values of the assets and liabilities and the respective tax bases. Tax rates utilized in calculating deferred income taxes generally represent the enacted statutory tax rates in the jurisdictions in which legal title of the underlying asset or liability resides. 
 
The preliminary fair value of “Deferred income tax assets” includes a $172 million adjustment to establish a valuation allowance for certain historical net operating losses that will not be fully realized as a result of the Merger.  Included in the fair value adjustment related to “Deferred income tax liabilities” is a $546 million adjustment reflecting a change in determination as to the reinvestment strategy of certain foreign operations of the company.

Integration and Separation Costs
Integration and separation costs have been and are expected to be significant. These costs to date primarily have consisted of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees associated with the preparation and execution of activities related to the Merger. These costs are recorded within Integration and separation costs in the Successor period and the costs are recorded within selling, general and administrative expenses in the Predecessor periods within the Consolidated Statements of Operations.
 
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Integration and separation costs
$
71

 
 
 
 
Selling, general and administrative expenses
 
$
210

$
122

$
581

$
222



17
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 4. Divestitures and Other Transactions

Merger Remedy - Divested Ag Business
As a condition of the regulatory approval of the Merger Transaction, the company is required to divest certain assets related to its Crop Protection business and research and development ("R&D") organization, specifically the company’s Cereal Broadleaf Herbicides and Chewing Insecticides portfolios, including Rynaxypyr®, Cyazypyr® and Indoxacarb as well as the Crop Protection R&D pipeline and organization, excluding seed treatment, nematicides, and late-stage R&D programs. On March 31, 2017, the company entered into a definitive agreement (the "FMC Transaction Agreement") with FMC Corporation ("FMC"). Under the FMC Transaction Agreement, FMC will acquire the Crop Protection business and R&D assets that DuPont is required to divest in order to obtain European Commission ("EC") approval of the Merger Transaction as described above, (the "Divested Ag Business") and DuPont has agreed to acquire certain assets relating to FMC’s Health and Nutrition segment, excluding its Omega-3 products, (the "Acquired H&N Business") (collectively, the "FMC Transactions"). The assets and liabilities related to the Divested Ag Business at September 30, 2017 are presented as held for sale in the interim Consolidated Balance Sheet. The sale of the Divested Ag Business meets the criteria for discontinued operations and as such, earnings are included within (loss) income from discontinued operations after income taxes for all periods presented.

On November 1, 2017, the company completed the FMC Transactions through the disposition of the Divested Ag Business and the acquisition of the Acquired H&N Business. The preliminary fair value as determined by the company of the Acquired H&N Business is $1,900 million. The FMC Transactions includes cash consideration payment to DuPont of approximately $1,200 million, which reflects the difference in value between the Divested Ag Business and the Acquired H&N Business, subject to  adjustments for inventory of the Divested Ag Business and net working capital of the Acquired H&N Business.

The company will apply the acquisition method of accounting in accordance with ASC 805, Business Combinations, to the Acquired H&N Business which requires the assets acquired and liabilities assumed to be recognized on the balance sheet at their fair values as of the acquisition date. As a result of the very recent closing of the FMC Transactions and the company's limited access to Acquired H&N Business information prior to the closing, the initial accounting for the business combination is incomplete at this time. As a result, the company is unable to provide amounts recognized as of the acquisition date for major classes of assets acquired and liabilities assumed. In addition, the company is unable to provide the supplemental pro forma revenue and earnings for the combined business. The company will include this information in its Annual Report on Form 10-K for the year ending December 31, 2017. 

The results of operations of the Divested Ag Business are presented as discontinued operations as summarized below:
 
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Net sales
$
116

$
191

$
271

$
1,068

$
1,077

Cost of goods sold
110

79

93

412

399

Other operating charges


5

4

17

14

Research and development expenses
9

24

32

95

101

Selling, general and administrative expenses
29

46

46

146

128

Restructuring and asset related charges - net
—

—

—

—

(3
)
Sundry income (expense) - net
—

—

(1
)
7

—

(Loss) income from discontinued operations before income taxes
(32
)
37

95

405

438

(Benefit from) provision for income taxes
(12
)
8

16

79

84

(Loss) Income from discontinued operations after income taxes
$
(20
)
$
29

$
79

$
326

$
354



18
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The following table presents depreciation and capital expenditures of the discontinued operations related to the Divested Ag Business:
 
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Depreciation
$
—

$
5

$
8

$
21

$
24

Capital expenditures
$
4

$
—

$
8

$
8

$
18


The carrying amount of major classes of assets and liabilities classified as assets and liabilities held for sale at September 30, 2017 and December 31, 2016 related to the Divested Ag Business consist of the following:
 
Successor
Predecessor
(In millions)
September 30, 2017
December 31, 2016
Cash and cash equivalents
$
125

$
57

Accounts and notes receivable - net
39

12

Inventories
973

323

Other current assets
1

1

Property, plant and equipment - net
523

380

Goodwill
145

11

Other intangible assets
1,360

—

Other assets
5

5

Assets held for sale
$
3,171

$
789

Accounts payable
62

27

Accrued and other current liabilities
13

12

Deferred income tax liabilities

—

6

Pension and other post employment benefits - noncurrent
12

—

Other noncurrent obligations
21

29

Liabilities held for sale
$
108

$
74


Food Safety Diagnostic Sale
In February 2017, the company completed the sale of its global food safety diagnostic business, a part of the Nutrition & Health business, to Hygiena LLC.  The sale resulted in a pre-tax gain of $162 million ($86 million net of tax). The gain was recorded in sundry income (expense) - net in the company's interim Consolidated Statement of Operations for the period January 1 through August 31, 2017.

DuPont (Shenzhen) Manufacturing Limited
In March 2016, the company recognized the sale of its 100 percent ownership interest in DuPont (Shenzhen) Manufacturing Limited to the Feixiang Group. The sale of the entity, which held certain buildings and other assets, resulted in a pre-tax gain of $369 million ($214 million net of tax). The gain was recorded in sundry income (expense) - net in the company's interim Consolidated Statement of Operations for the nine months ended September 30, 2016.
Performance Chemicals
On July 1, 2015, DuPont completed the separation of its Performance Chemicals segment through the spin-off of all of the issued and outstanding stock of The Chemours Company (the "Separation"). In connection with the Separation, the company and The Chemours Company ("Chemours") entered into a Separation Agreement, discussed below, and a Tax Matters Agreement and certain ancillary agreements, including an employee matters agreement, agreements related to transition and site services, and intellectual property cross licensing arrangements. In addition, the companies have entered into certain supply agreements.


19
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Separation Agreement
The company and Chemours entered into a Separation Agreement that sets forth, among other things, the agreements between the company and Chemours regarding the principal transactions necessary to effect the Separation and also sets forth ancillary agreements that govern certain aspects of the company’s relationship with Chemours after the separation. Among other matters, the Separation Agreement and the ancillary agreements provide for the allocation between DuPont and Chemours of assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after the completion of the Separation.

Pursuant to the Separation Agreement, Chemours indemnifies DuPont against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the distribution. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In 2017, DuPont and Chemours amended the Separation Agreement to provide for a limited sharing of potential future PFOA liabilities for a period of five years beginning July 6, 2017. See Note 13 for further information. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. At September 30, 2017, the indemnified assets are $96 million within accounts and notes receivable - net and $342 million within other assets on the interim Condensed Consolidated Balance Sheet. See Note 13 for further discussion of certain litigation and environmental matters indemnified by Chemours.

Income (loss) from discontinued operations after taxes in the company's interim Consolidated Statement of Operations during the period January 1 through August 31, 2017 reflects a tax benefit of $10 million associated with an adjustment to the tax benefit recognized in the first quarter of 2017 related to the charge for the perfluorooctanoic acid ("PFOA") multi-district litigation settlement. Income (loss) from discontinued operations after taxes for the period January 1 through August 31, 2017 includes a charge of $335 million ($214 million net of tax) in connection with the PFOA multi-district litigation settlement. See Note 13 for further discussion. Income (loss) from discontinued operations after taxes during the three and nine months ended September 30, 2016, includes $10 million and $30 million, respectively, of costs in connection with the separation transaction primarily related to professional fees associated with preparation of regulatory filings and separation activities within finance, tax, legal, and information system functions.
Note 5. Restructuring and Asset Related Charges

DowDuPont Cost Synergy Program
In September 2017, DowDuPont approved initial post-merger actions under the DowDuPont Cost Synergy Program (the “Synergy Program”) which is designed to integrate and optimize the organization following the Merger and Intended Business Separations. In connection with the approved actions under the Synergy Program, DuPont expects to incur pre-tax charges of approximately $70 million, comprised primarily of severance and related benefit costs. For the period September 1 through September 30, 2017, the company recognized pre-tax charges of $40 million in restructuring and asset related charges - net in the company's interim Consolidated Statements of Operations. These actions are expected to be substantially complete by the end of 2018.

DuPont account balances and activity for the DowDuPont Cost Synergy Program are summarized below:
(In millions)
Severance and Related Benefit Costs
Charges to (loss) income from continuing operations for the period September 1 through September 30, 2017 (Successor)
$
40

Payments
(1
)
Non-cash compensation
(7
)
Balance as of September 30, 2017
$
32



20
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

On November 1, 2017, the company approved additional restructuring actions under the Synergy Program, adopted by the DowDuPont Board of Directors. Based on all actions approved to date under the Synergy Program, DuPont expects to record total pre-tax restructuring charges of about $850 million, comprised of approximately $350 million to $400 million of severance and related benefits costs; up to $360 million of asset related charges, and $110 million to $140 million of costs related to contract terminations. DuPont’s current estimated total pre-tax restructuring charges include the $40 million recorded for the period September 1 through September 30, 2017, comprised of severance and related benefit costs. DuPont expects to record pre-tax restructuring charges of approximately $115 million in the fourth quarter of 2017, with the remaining restructuring charges to be incurred by the end of 2019. The Synergy Program includes certain asset actions, including strategic decisions regarding the cellulosic biofuel business reflected in the preliminary fair value measurement of DuPont’s assets as of the merger date. Current estimated total pre-tax restructuring charges could be impacted by future adjustments to the preliminary fair value of DuPont’s assets.

2017 Restructuring Program
During the first quarter 2017, DuPont committed to take actions to improve plant productivity and better position its businesses for productivity and growth before and after the anticipated closing of the Merger Transaction (the "2017 restructuring program"). In connection with these actions, the company incurred pre-tax charges of $1 million and $313 million, during the period July 1 through August 31, 2017 and January 1 through August 31, 2017 ("Predecessor" periods), respectively, recognized in restructuring and asset related charges - net in the company's interim Consolidated Statements of Operations. The charge for the period July 1 through August 31, 2017 is severance and related benefit costs. The charge for the period January 1 through August 31, 2017 is comprised of $279 million of asset-related charges and $34 million in severance and related benefit costs. The charges primarily relate to the second quarter closure of the Protection Solutions business Cooper River manufacturing site located near Charleston, South Carolina. The asset-related charges mainly consist of accelerated depreciation associated with the closure. The actions associated with this plan are expected to be substantially complete by the end of 2017.

Account balances and activity for the 2017 restructuring program are summarized below:

(In millions)
Severance and Related Benefit Costs
Asset Related Charges1
Total
Charges to income from continuing operations for the period January 1 through August 31, 2017 (Predecessor)
$
34

$
279

$
313

Payments
(8
)
—

(8
)
Asset write-offs
—

(279
)
$
(279
)
Balance as of August 31, 2017
$
26

$
—

$
26

 
 
 
 
Charges to income from continuing operations for the period September 1 through September 30, 2017 (Successor)
$
—

$
—

$
—

Payments
(1
)
—

(1
)
Balance as of September 30, 2017
$
25

$
—

$
25

1. 
Includes accelerated depreciation related to site closure. Charge for accelerated depreciation represents the difference between the depreciation expense to be recognized over the revised useful life of the site, based upon the anticipated date the site will be closed and depreciation expense as determined utilizing the useful life prior to the restructuring action.

La Porte Plant, La Porte, Texas
In March 2016, DuPont announced its decision to not re-start the Agriculture business's insecticide manufacturing facility at the La Porte site located in La Porte, Texas.  The facility manufactured Lannate® and Vydate® insecticides and has been shut down since November 2014.  As a result of this decision, during the nine months ended September 30, 2016, a pre-tax charge of $75 million was recorded in restructuring and asset related charges - net in the company's interim Consolidated Statement of Operations which included $41 million of asset related charges, $18 million of contract termination costs, and $16 million of employee severance and related benefit costs.                                                                                                                                                                             

2016 Global Cost Savings and Restructuring Plan
At September 30, 2017, total liabilities related to the program were $35 million. A complete discussion of restructuring initiatives is included in the company's 2016 Annual Report in Note 4, "Restructuring and Asset Related Charges - Net." In connection with these actions, the company incurred pre-tax charges of $10 million during the period July 1 through August 31, 2017, recognized in restructuring and asset related charges - net in the company’s interim Consolidated Statement of Operations. This was due to additional severance payments owed to previously terminated executives that became probable during the period.

21
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS


Account balances and activity for the restructuring program are summarized below:
(In millions)
Severance and Related Benefit Costs
Other Non-Personnel Charges1
Total
Balance at December 31, 2016 (Predecessor)
$
100

$
22

$
122

Payments
(76
)
(11
)
(87
)
Net translation adjustment
2

—

2

  Other adjustments
10

—

10

Balance as of August 31, 2017
$
36

$
11

$
47

 
 
 
 
Balance at September 1, 2017 (Successor)
$
36

$
11

$
47

Payments
(11
)
(1
)
(12
)
Balance as of September 30, 2017
$
25

$
10

$
35

1.
Other non-personnel charges consist of contractual obligation costs.

During the three months ended September 30, 2016, a net charge of $17 million was recorded, consisting of $14 million of restructuring and asset related charges - net and $3 million in sundry income (expense) -net in the company's interim Consolidated Statement of Operations. During the nine months ended September 30, 2016, a net (benefit) charge of $(68) million was recorded, consisting of $(71) million in restructuring and asset related charges - net and $3 million in sundry income (expense)-net in the company's interim Consolidated Statement of Operations. This was primarily due to a reduction in severance and related benefit costs partially offset by the identification of additional projects in certain businesses. The reduction in severance and related benefit costs was driven by the elimination of positions at a lower cost than expected as a result of redeployments and attrition as well as lower than estimated individual severance costs.

Asset Impairment
During the third quarter 2016, the company recognized a $158 million pre-tax impairment charge in restructuring and asset related charges - net in the company's interim Consolidated Statements of Operations related to indefinite-lived intangible trade names within the Industrial Biosciences business. In connection with business strategy reviews and brand realignment conducted during the third quarter 2016, the company decided to phase out the use of certain acquired trade names within the business resulting in a change from an indefinite life to a finite useful life for these assets. As a result of these changes, the carrying value of the trade name assets exceeded the fair value.

The basis of the fair value for the charges was calculated utilizing an income approach (relief from royalty method) using Level 3 inputs within the fair value hierarchy, as described in the company’s 2016 Annual Report in Note 1, “Summary of Significant Accounting Policies.” The key assumptions used in the calculation included projected revenue, royalty rates and discount rates. These key assumptions involve management judgment and estimates relating to future operating performance and economic conditions that may differ from actual cash flows. After the recognition of the impairment charge, the remaining net book value of the trade names was $28 million, which represented fair value.


22
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 6.  Supplementary Information
Sundry Income (Expense) - Net
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Royalty income1
 
$
11

$
27

$
84

$
108

Interest income
$
12

26

30

83

71

Equity in (losses) earnings of affiliates - net
(4
)
13

22

55

60

Net gain on sales of businesses and other assets2,3
1

2

—

205

384

Net exchange gains (losses)
77

(195
)
(76
)
(394
)
(212
)
Miscellaneous income and expenses - net4
2

31

(18
)
133

(4
)
Sundry income (expense) - net
$
88

$
(112
)
$
(15
)
$
166

$
407

 
1. 
In the Successor period, royalty income of $9 million is included in Net Sales.
2.  
Includes a pre-tax gain of $162 million ($86 million net of tax) for the period January 1 through August 31, 2017 related to the sale of the global food safety diagnostic business. See Note 4 for additional information.
3.  
Includes a pre-tax gain of $369 million ($214 million net of tax) for the nine months ended September 30, 2016 related to the sale of DuPont (Shenzhen) Manufacturing Limited. See Note 4 for additional information.
4.  
Miscellaneous income and expenses - net, includes interest items, gains (losses) on available for sale securities, gains related to litigation settlements, licensing income, gains on purchases, and other items.

The following table summarizes the impacts of the company's foreign currency hedging program on the company's results of operations. The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the United States (U.S.), whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in sundry income (expense) - net and the related tax impact is recorded in provision for income taxes on continuing operations in the interim Consolidated Statements of Operations.
 
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Subsidiary Monetary Position (Loss) Gain
 
 
 
 
 
Pre-tax exchange (loss) gain
$
(35
)
$
65

$
6

$
37

$
185

Local tax (expenses) benefits
(31
)
88

18

217

(29
)
Net after-tax impact from subsidiary exchange (loss) gain
$
(66
)
$
153

$
24

$
254

$
156

 
 
 
 
 
 
Hedging Program Gain (Loss)
 
 
 
 
 
Pre-tax exchange gain (loss)
$
112

$
(260
)
$
(82
)
$
(431
)
$
(397
)
Tax (expenses) benefits
(40
)
94

30

155

143

Net after-tax impact from hedging program exchange gain (loss)
$
72

$
(166
)
$
(52
)
$
(276
)
$
(254
)
 
 
 
 
 
 
Total Exchange Gain (Loss)
 
 
 
 
 
Pre-tax exchange gain (loss)
$
77

$
(195
)
$
(76
)
$
(394
)
$
(212
)
Tax (expenses) benefits
$
(71
)
$
182

$
48

$
372

$
114

Net after-tax exchange gain (loss)
$
6

$
(13
)
$
(28
)
$
(22
)
$
(98
)



23
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 7.  Income Taxes 

Effective with the Merger, the company and Dow are subsidiaries of DowDuPont. The company is included in DowDuPont consolidated tax groups and related income tax returns within certain jurisdictions. The company will continue to record a separate tax liability for its share of the taxable income and tax attributes and obligations on DowDuPont’s consolidated income tax returns following a formula consistent with the economic sharing of tax attributes and obligations. Dow and DuPont compute the amount due to DowDuPont for their share of taxable income and tax attributes on DowDuPont’s consolidated tax return. The amounts reported as income tax payable or receivable represent the company’s payment obligation (or refundable amount) to DowDuPont based on a theoretical tax liability calculated based on the methodologies agreed, elected or required in each combined or consolidated filing jurisdiction.

Each year the company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the company. As a result, there is an uncertainty in income taxes recognized in the company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. It is reasonably possible that changes to the company's global unrecognized tax benefits could be significant; however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of increases or decreases that may occur within the next twelve months cannot be made.

During the period January 1 through August 31, 2017, the company recognized tax expense of $29 million associated with the elimination of the U.S. domestic manufacturing deduction recorded in 2016 due to taxable income limitations triggered by the Company's decision to deduct the second quarter 2017 principal U.S. pension plan contribution on its 2016 consolidated U.S. tax return.

Additionally, during the period January 1 through August 31, 2017, the company recognized a tax benefit of $57 million, as well as a pre-tax benefit of $50 million on associated accrued interest reversals, related to a reduction in the company's unrecognized tax benefits due to the closure of various tax statutes of limitations. Income from continuing operations during the period January 1 through August 31, 2017 includes a tax benefit of $53 million and a pre-tax benefit of $47 million for accrued interest reversals (recorded in sundry income (expense) - net). Income (loss) from discontinued operations after taxes during the period January 1 through August 31, 2017 includes a tax benefit of $4 million and a pre-tax benefit of $3 million for the accrued interest reversal.


24
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 8.  Earnings Per Share of Common Stock
Set forth below is a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the Predecessor periods indicated below:
 
Predecessor
 
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Numerator:
 
 
 
 
(Loss) income from continuing operations after income taxes attributable to DuPont
(263
)
(70
)
1,624

1,902

Preferred dividends
(2
)
(2
)
(7
)
(7
)
(Loss) income from continuing operations after income taxes available to DuPont common stockholders
$
(265
)
$
(72
)
$
1,617

$
1,895

 
 
 
 
 
Income from discontinued operations after income taxes available to DuPont common stockholders
29

72

117

346

 
 
 
 
 
Net (loss) income available to common stockholders
$
(236
)
$
—

$
1,734

$
2,241

 
 
 
 
 
Denominator:
 
 
 
 
Weighted-average number of common shares outstanding - Basic
868,992,000

874,292,000

867,888,000

874,274,000

Dilutive effect of the company’s employee compensation plans1
—

5,099,000

4,532,000

4,332,000

Weighted-average number of common shares outstanding - Diluted1
868,992,000

879,391,000

872,420,000

878,606,000

1. 
Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

The following average number of stock options were antidilutive, and therefore not included in the dilutive earnings per share calculations:
 
Predecessor
 
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Average number of stock options
4,832,000

4,558,000

1,906

4,885,000



25
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 9. Inventories 
 
Successor
Predecessor
(In millions)
September 30,
2017
December 31,
2016
Finished products
$
4,132

$
2,961

Semi-finished products
3,310

1,877

Raw materials
388

292

Stores and supplies
336

398

Total
8,166

5,528

Adjustment of inventories to a last-in, first-out (LIFO) basis
617

(178
)
Total inventories
$
8,783

$
5,350


Total inventories increased $3,433 million from December 31, 2016, primarily reflecting inventory at fair value at the date of the Merger. See Note 3 for additional information regarding the Merger.

Note 10. Property

 
Successor
Predecessor
(In millions)
September 30, 2017
December 31, 2016
Land and land improvements
$
941

$
501

Buildings
2,558

4,224

Machinery and equipment
7,559

16,909

Construction in progress
965

1,381

Total property, plant and equipment
12,023

23,015

Accumulated depreciation
(121
)
(14,164
)
Total property, plant and equipment - net

$
11,902

$
8,851


Net property increased $3,051 million from December 31, 2016, primarily reflecting property, plant and equipment at fair value at the date of the Merger. See Note 3 for additional information regarding the Merger.

Equipment and buildings are depreciated over useful lives on a straight-line basis ranging from 1 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over 1 to 8 years.

 
Successor
Predecessor
(In millions)
For the Period
September 1 - September 30, 2017
For the Period
July 1 - August 31, 2017
Three Months Ended
September 30, 2016
For the Period
Jan. 1 - August 31, 2017
Nine Months Ended
September 30, 2016
Depreciation expense
$
111

$
143

$
226

$
589

$
683




26
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 11.  Other Intangible Assets 

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: 
 
Successor
Predecessor
 
September 30, 2017
December 31, 2016
 
Gross
Accumulated
Amortization
Net
Gross
Accumulated
Amortization
Net
Intangible assets subject to amortization (Definite-lived):
 

 

 

 

 

 

Customer-related
$
9,383

$
(45
)
$
9,338

$
1,574

$
(586
)
$
988

Developed technology
4,112

(34
)
4,078

1,410

(838
)
572

Trademarks/trade names
1,071

(6
)
1,065

53

(15
)
38

Microbial cell factories1
430

(2
)
428

 
 
 
Other2
297

(2
)
295

171

(82
)
89

Total other intangible assets with finite lives
15,293

(89
)
15,204

3,208

(1,521
)
1,687

 
 
 
 
 
 
 
Intangible assets not subject to amortization (Indefinite-lived):
 

 

 

 

 

 

In-process research and development ("IPR&D")
655

—

655

73

—

73

Microbial cell factories1
 
 
 
306

—

306

Germplasm3
6,773

—

6,773

1,053

—

1,053

Trademarks / trade names
5,036

—

5,036

545

—

545

Total other intangible assets
12,464

—

12,464

1,977

—

1,977

Total
$
27,757

$
(89
)
$
27,668

$
5,185

$
(1,521
)
$
3,664

1. 
Microbial cell factories, derived from natural microbes, are used to sustainably produce enzymes, peptides and chemicals using natural metabolic processes. The company recognized the microbial cell factories as intangible assets upon the acquisition of Danisco. As a result of the valuation as part of the merger, it was determined that this now has a definite life and therefore it has been moved from indefinite-lived to definite-lived as of September 1, 2017.
2. 
Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements.
3. 
Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The company recognized germplasm as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.

In connection with the Merger, the company recorded $27,844 million of intangible assets, as shown in the table below, representing the preliminary fair values at the Merger date. See Note 3 for additional information regarding the Merger.

Intangible Assets
Gross Carrying Amount
Weighted-average Amortization Period (years)
(In millions)
Intangible assets with finite lives:
 
 
  Customer-related
$
9,434

18
  Developed technology
4,124

12
  Trademarks/trade names
1,073

12
  Microbial cell factories
430

23
  Other
294

15
Total other intangible assets with finite lives
$
15,355

 
Intangible assets with indefinite lives:
 
 
  IPR&D
$
655


Germplasm
6,773


  Trademarks/trade names
5,061


Total intangible assets
$
27,844

 


27
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was $89 million for the period September 1 through September 30, 2017, $31 million for the period July 1 through August 31, 2017, and $139 million for the period January 1 through August 31, 2017. The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was $46 million and $272 million for the three and nine months ended September 30, 2016.

Total estimated amortization expense for the next five fiscal years is as follows:
(In millions)
 
2017
$
512

2018
1,096

2019
1,090

2020
1,080

2021
1,067

2022
1,060


Note 12.  Short-term borrowings, Long-term Debt and Available Credit Facilities

The following tables summarize the company's short-term borrowings and capital lease obligations and long-term debt:

Short-term borrowings and capital lease obligations
Successor
Predecessor
(In millions)
September 30, 2017
December 31, 2016
Commercial paper
$
3,244

$
386

Other loans - various currencies
48

39

Long-term debt payable within one year
1,328

4

Repurchase facility
1,300

—

Total short-term borrowings and capital lease obligations
$
5,920

$
429


Long Term Debt
Successor1
Predecessor
 
September 30, 2017
December 31, 2016
(In millions)
Amount
Weighted Average Rate
Amount
Promissory notes and debentures:
 
 
 
  Final maturity 2018
$
1,293

1.59
%
$
1,290

  Final maturity 2019
525

2.23
%
500

  Final maturity 2020
3,079

1.78
%
999

  Final maturity 2021
1,586

2.07
%
1,498

  Final maturity 2023 and thereafter
3,496

3.32
%
3,188

Other facilities:
 
 
 
Term loan due 2019
1,000

2.24
%
500

Other loans
19

4.32
%
22

Foreign currency loans, various rates and maturities
30

2.84
%
29

Medium-term notes, varying maturities through 2043
110

0.98
%
111

Capital lease obligations
5



9

Less: Unamortized debt discount and issuance costs
—



35

Less: Long-term debt due within one year
1,328



4

Total
$
9,815

 
$
8,107

1. 
The Successor period includes the reflection of debt at fair value at the date of the Merger. See Note 3 for additional information regarding the Merger.

28
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Principal payments of long-term debt for the next five years are as follows:
Maturities of Long-Term Debt For Next Five Years
 
(In millions)
 
2017
$
2

2018
1,284

2019
1,505

2020
3,005

2021
1,505

2022
2


Available Committed Credit Facilities
The following table summarizes the company's credit facilities:
Committed and Available Credit Facilities at September 30, 2017 (Successor)
 
 
(In millions)
Effective Date
Committed Credit
Credit Available
Maturity Date
Interest
DuPont Revolving Credit Facility
March 2016
$
3,000

$
2,945

May 2019
Floating Rate
DuPont Term Loan Facility
March 2016
4,500

3,500

March 2019
Floating Rate
Repurchase Facility (see below)
January 2017
1,300

—

November 2017
Floating Rate
Total Committed and Available Credit Facilities
 
$
8,800

$
6,445

 
 

Debt Offering
In May 2017, the company completed an underwritten public offering of $1,250 million of the company's 2.20 percent Notes due 2020 and $750 million of the company's Floating Rate Notes due 2020 (the "May 2017 Debt Offering"). The proceeds of this offering were used to make a discretionary pension contribution to the company's principal U.S. pension plan. See Note 15 for further discussion regarding this contribution.

Repurchase Facility
In January 2017, the company entered into a committed receivable repurchase agreement of up to $1,300 million (the "Repurchase Facility"). The Repurchase Facility is structured to account for the seasonality of the agriculture business and expires on November 30, 2017. Under the Repurchase Facility, the company may sell a portfolio of available and eligible outstanding customer notes receivables within the Agriculture business to participating institutions and simultaneously agree to repurchase such notes receivable at a future date. The Repurchase Facility is considered a secured borrowing with the customer notes receivables utilized as collateral. The amount of collateral required equals 105 percent of the outstanding borrowing amounts. Borrowings under the Repurchase Facility have an interest rate of the London interbank offered rate ("LIBOR") plus 0.75 percent.

As of September 30, 2017, $1,365 million of notes receivable, recorded in accounts and notes receivable - net, were pledged as collateral against outstanding borrowings under the Repurchase Facility of $1,300 million, recorded in Short-term borrowings and capital lease obligations on the interim Consolidated Balance Sheet.

Term Loan Facility
In March 2016, the company entered into a credit agreement that provides for a three-year, senior unsecured term loan facility in the aggregate principal amount of $4,500 million (as amended from time to time, the "Term Loan Facility"). In the first quarter of 2017, the Term Loan Facility was amended to extend the date on which the commitment to lend terminates. As a result, DuPont may make up to seven term loan borrowings through July 27, 2018; amounts repaid or prepaid are not available for subsequent borrowings. The Term Loan Facility matures in March 2019 at which time all outstanding borrowings, including accrued but unpaid interest, become immediately due and payable. As of September 30, 2017, the company had borrowed $1,000 million and had unused commitments of $3,500 million under the Term Loan Facility.

In October 2017, under the Term Loan Facility, DuPont borrowed $500 million at the LIBOR Loan Rate, primarily to pay down commercial paper.

29
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 13.  Commitments and Contingent Liabilities 
Guarantees 
Indemnifications
In connection with acquisitions and divestitures as of September 30, 2017, the company has indemnified respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. In addition, the company indemnifies its duly elected or appointed directors and officers to the fullest extent permitted by Delaware law, against liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future payments is generally unlimited.

Obligations for Equity Affiliates & Others 
The company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates, customers and suppliers. Additionally, in connection with the Separation, the company has directly guaranteed Chemours' purchase obligations under an agreement with a third-party supplier. At September 30, 2017 and December 31, 2016, the company had directly guaranteed $323 million and $388 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the company could be required to make under the guarantees. The company would be required to perform on these guarantees in the event of default by the guaranteed party.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

In certain cases, the company has recourse to assets held as collateral, as well as personal guarantees from customers and suppliers. Assuming liquidation, these assets are estimated to cover 16 percent of the $111 million of guaranteed obligations of customers and suppliers as of September 30, 2017.

The following tables provide a summary of the final expiration and maximum future payments for each type of guarantee:
Guarantees at September 30, 2017 (Successor)
Final Expiration
Maximum Future Payments
(In millions)
Obligations for customers and suppliers1:
 
 
Bank borrowings
2022
$
111

Obligations for non-consolidated affiliates2:



Bank borrowings
2017
164

Obligations for Chemours3:



Chemours' purchase obligations
2018
11

Residual value guarantees4
2029
37

Total guarantees
 
$
323

1.
Existing guarantees for customers and suppliers, as part of contractual agreements.
2.   
Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.
3.
Guarantee for Chemours' raw material purchase obligations under agreement with third party supplier.
4.
The company provides guarantees related to leased assets specifying the residual value that will be available to the lessor at lease termination through sale of the assets to the lessee or third parties.

Litigation
The company is subject to various legal proceedings arising out of the normal course of its business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Although considerable uncertainty exists, management does not anticipate that the ultimate disposition of these matters will have a material adverse effect on the company's results of operations, consolidated financial position or liquidity.  However, the ultimate liabilities could be material to results of operations in the period recognized.


30
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

PFOA
DuPont used PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt), as a processing aid to manufacture some fluoropolymer resins at various sites around the world including its Washington Works plant in West Virginia. At September 30, 2017, DuPont had a total accrual balance of $15 million related to the PFOA matters discussed below and has recorded a total indemnification asset of $15 million.

Leach v. DuPont
In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds approximately 80,000 residents, pursuant to which DuPont paid the plaintiffs' attorneys' fees and expenses of $23 million and made a payment of $70 million that class counsel designated to fund a community health project (the "Leach Settlement"). In addition, the company funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the "C8 Science Panel"). The C8 Science Panel found probable links, as defined in the Leach Settlement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol.

Under the Leach Settlement, the company is obligated to fund up to $235 million for a medical monitoring program for eligible class members and, in addition, administrative costs associated with the program, including class counsel fees. In January 2012, the company established and put $1 million into an escrow account to fund medical monitoring as required by the settlement agreement. As of September 30, 2017, less than $1 million had been disbursed from the account. While it is probable that the company will incur liabilities related to funding the medical monitoring program, the company does not expect any such liabilities to be material. In addition, under the Leach Settlement, the company must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association, and private well users.

Multi-District Litigation
Leach class members may pursue personal injury claims against DuPont only for the six human diseases for which the C8 Science Panel determined a probable link exists. Following the Leach Settlement, approximately 3,550 lawsuits alleging personal injury claims were filed in various federal and state courts in Ohio and West Virginia. These lawsuits are consolidated in multi-district litigation ("MDL") in the U.S. District Court for the Southern District of Ohio.

In the first quarter of 2017, the MDL was settled for $670.7 million in cash (the "MDL Settlement"), half of which was to be paid by Chemours and half paid by DuPont. At September 30, 2017, all payments under the settlement agreement have been made by both companies. DuPont’s payment is not subject to indemnification or reimbursement by Chemours.  In exchange for that payment, DuPont and Chemours receive releases of all claims by the settling plaintiffs. The MDL Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by DuPont or Chemours. Claims from a small number of plaintiffs opting out of the MDL Settlement remain pending.

Additional Actions
Since 2006, DuPont has undertaken obligations under agreements with the U.S. Environmental Protection Agency ("EPA"), including a 2009 consent decree under the Safe Drinking Water Act (the "Order"), and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national health advisory level, even if provisional, as established from time to time by the EPA. A provisional health advisory level was set in 2009 at 0.4 parts per billion ("ppb") for PFOA in drinking water considering episodic exposure. In May 2016, the EPA announced a health advisory level of 0.07 ppb for PFOA in drinking water considering lifetime versus episodic exposure. In January 2017, the EPA announced it had amended the Order to include Chemours, and to make the new health advisory level the trigger for additional actions by DuPont and Chemours, thus expanding the obligations to the EPA beyond the previously established testing and water supply commitments around the Washington Works facility. The company's accrual at September 30, 2017, includes $15 million related to these obligations and voluntary commitments.


31
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Concurrent with the MDL Settlement, DuPont and Chemours amended the Separation Agreement to provide for a limited sharing of potential future PFOA liabilities (i.e., indemnifiable losses, as defined in the Separation Agreement) for a period of five years beginning July 6, 2017. During that five-year period, Chemours will annually pay future PFOA liabilities up to $25 million and, if such amount is exceeded, DuPont would pay any excess amount up to the next $25 million (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess liabilities. After the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the Separation Agreement would continue unchanged.  There have been no charges incurred by DuPont under this arrangement through September 30, 2017. Chemours has also agreed that it will not contest its liability to DuPont under the Separation Agreement for PFOA liabilities on the basis of ostensible defenses generally applicable to the indemnification provisions under the Separation Agreement, including defenses relating to punitive damages, fines or penalties or attorneys’ fees, and waives any such defenses with respect to PFOA liabilities.  Chemours has, however, retained defenses as to whether any particular PFOA claim is within the scope of the indemnification provisions of the Separation Agreement.

It is possible that new lawsuits could be filed against DuPont related to PFOA that may not be within the scope of the MDL Settlement. Any such new litigation would be subject to indemnification by Chemours under the Separation Agreement, as amended.

Prior to the separation of Chemours, the company introduced GenX as a polymerization processing aid at the Fayetteville Works facility in North Carolina. The facility is now owned and operated by Chemours which continues to manufacture and use GenX as a polymerization processing aid. Chemours is responding to ongoing inquiries and investigations from federal, state and local investigators, regulators and other governmental authorities as well as inquiries from the media and local community stakeholders. These inquiries and investigations involve the discharge of the polymerization processing aid GenX and certain similar compounds from the Chemours’ facility in Fayetteville, North Carolina into the Cape Fear River.

In August 2017, the U.S. Attorney’s Office for the Eastern District of North Carolina served the company with a subpoena for testimony and the production of documents to a grand jury.  The subpoena seeks documents related to alleged discharges of PFOA and/or GenX, (the replacement product for PFOA) from the Fayetteville Works facility into the Cape Fear River in Bladen County, North Carolina.

In the fourth quarter of 2017, lawsuits, including purported class actions, were filed against Chemours and the company, one of which also names DowDuPont, alleging that certain perflourinated chemicals, discharged into the Cape Fear River, Bladen County, North Carolina, from the operations and wastewater treatment at the Fayetteville Works facility, contaminated the water supply causing economic or property damage. It is possible that these ongoing inquiries and investigations, including the grand jury subpoena, could result in penalties or sanctions, or that additional litigation will be instituted against Chemours and/or the company. The company has an indemnification claim against Chemours with respect to current and future inquiries, investigations, and claims, including lawsuits, related to the foregoing.
 
Environmental 
Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At September 30, 2017, the company had accrued obligations of $455 million for probable environmental remediation and restoration costs, including $74 million for the remediation of Superfund sites. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the interim Consolidated Balance Sheets. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to $910 million above the amount accrued at September 30, 2017. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the company’s results of operations, financial condition and cash flows. It is the opinion of the company’s management, however, that the possibility is remote that costs in excess of the range disclosed will have a material impact on the company’s results of operations, financial condition or cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. At December 31, 2016, the company had accrued obligations of $457 million for probable environmental remediation and restoration costs, including $17 million for the remediation of Superfund sites.

Pursuant to the DuPont and Chemours Separation Agreement, the company